Results 111 to 120 of about 22,217 (248)

Genetic Diversity of African Trypanosomes in Tsetse Flies and Cattle From the Kafue Ecosystem

open access: yesFrontiers in Veterinary Science, 2021
We clarified the genetic diversity of Trypanosoma spp. within the Kafue ecosystem, using PCR targeting the internal transcribed spacer 1 and the cathepsin L-like cysteine protease (CatL) sequences. The overall prevalence of Trypanosoma spp. in cattle and
Yukiko Nakamura   +11 more
doaj   +1 more source

Identification of human-infective trypanosomes in animal reservoir of sleeping sickness in Uganda by means of serum-resistance-associated (SRA) gene.

open access: yes, 2001
BACKGROUND: The expansion of sleeping sickness caused by Trypanosoma brucei rhodesiense beyond its traditional focus in southeast Uganda has been linked with large-scale livestock restocking.
Carrington, M   +6 more
core   +1 more source

How are Trypanosoma brucei receptors protected from host antibody‐mediated attack?

open access: yesBioEssays, Volume 46, Issue 7, July 2024.
Trypanosoma brucei acquires host macromolecular nutrients such as transferrin (Tf) and haptoglobin‐hemoglobin (Hp‐Hb) for their survival. This process is mediated by specific receptors embedded within VSG coat, which is constantly at risk of being recognized by host anti‐receptor antibodies.
Sourav Banerjee   +3 more
wiley   +1 more source

The origins of a new Trypanosoma brucei rhodesiense sleeping sickness outbreak in eastern Uganda.

open access: yes, 2001
BACKGROUND: Sleeping sickness, caused by two trypanosome subspecies, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, is a parasitic disease transmitted by the tsetse fly in sub-Saharan Africa.
Coleman, PG   +5 more
core   +1 more source

Trypanosoma brucei aquaglyceroporin 2 is a high-affinity transporter for pentamidine and melaminophenyl arsenic drugs and the main genetic determinant of resistance to these drugs. [PDF]

open access: yes, 2013
OBJECTIVES: Trypanosoma brucei drug transporters include the TbAT1/P2 aminopurine transporter and the high-affinity pentamidine transporter (HAPT1), but the genetic identity of HAPT1 is unknown. We recently reported that loss of T.
Aguinaga Andrés, David   +19 more
core   +3 more sources

Novel quinoline derivatives with broad‐spectrum antiprotozoal activities

open access: yesArchiv der Pharmazie, Volume 357, Issue 6, June 2024.
Several quinoline derivatives incorporating arylnitro and aminochalcone moieties were synthesized and evaluated in vitro against a broad panel of trypanosomatid protozoan parasites. Compounds 2c, 2d, and 4i displayed submicromolar activity against Trypanosoma brucei rhodesiense, with high selectivity relative to human lung fibroblasts and mouse primary
Carla B. Hartman   +6 more
wiley   +1 more source

Reanalyzing the 1900–1920 Sleeping Sickness Epidemic in Uganda

open access: yesEmerging Infectious Diseases, 2004
Sleeping sickness has long been a major public health problem in Uganda. From 1900 to 1920, more than 250,000 people died in an epidemic that affected the southern part of the country, particularly the Busoga region.
E.M. Fèvre   +3 more
doaj   +1 more source

Kinetoplastids:related protozoan pathogens, different diseases [PDF]

open access: yes, 2008
Kinetoplastids are a group of flagellated protozoans that include the species Trypanosoma and Leishmania, which are human pathogens with devastating health and economic effects. The sequencing of the genomes of some of these species has highlighted their
Agranoff   +127 more
core   +3 more sources

Treatment of mucocutaneous leishmaniasis – A systematic review

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 22, Issue 6, Page 763-773, June 2024.
Summary Mucocutaneous leishmaniasis is a severe infectious disease, predominantly endemic in Central and South America and is characterized by granulomatous, destructive mucosal lesions in the oral, nasal, and pharyngeal cavities. It is caused by protozoa of the genus Leishmania spp. transmitted to humans by sandflies.
Theresa Fischer   +3 more
wiley   +1 more source

Behandlung der mukokutanen Leishmaniose – eine systematische Übersicht

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, Volume 22, Issue 6, Page 763-774, June 2024.
Zusammenfassung Die mukokutane Leishmaniose ist eine schwere Infektionskrankheit, die überwiegend in Zentral‐ und Südamerika endemisch ist und sich klinisch mit granulomatösen, destruierenden Schleimhautläsionen im Mund‐Nasen‐Rachenraum manifestiert. Sie wird durch Protozoen, Leishmania spp., ausgelöst, die durch Sandmücken auf den Menschen übertragen ...
Theresa Fischer   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy